Skip to content

Evaluation of safety and efficacy of NEUROCAF in healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of NEUROCAF on Brain Health and Cognitive function in Healthy Subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028558
Enrollment
70
Registered
2020-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NEUROCAF: oral administration of single dose of NEUROCAF capsules everyday for 84 days Control Intervention1: Placebo: oral administration of single dose of Placebo capsules everyday fo

Sponsors

Vidya Herbs Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with normal cognitive function 2. Subjects with a MMSE Score equal or greater than 23 3. Diabetes, hypertension and other medical condition patients should be on stable medication for last 3 months 4. Should not be an any medication for cognition and other neurological disorders 5. Females of childbearing age, agree to use approved birth control methods during the study, and have negative urine pregnancy test (UPT) at screening 6. Non-smokers 7. Able to communicate verbally, able to write and speak English and comfortable with using computer 8. Must be willing and able to give informed consent and comply with the study procedures.

Exclusion criteria

Exclusion criteria: 1. Subjects with history of Respiratory bacterial or viral infection (including COVID-19) in the past 2 weeks,Psychiatric disorders ,Severe neurological diseases or seizures,Uncontrolled / serious medical illness including diabetes, liver disease, hypertension,Cardiac Disease/Neurological Problems,Auto-immune disease (rheumatoid arthritis, lupus, type 1 diabetes),Gastrointestinal tract bleeding / peptic ulcer disease 2. Subjects who maybe allergic to any of the natural constituents of the Investigational Product. 3. Known HIV or Hepatitis B positive or any other immuno-compromised state 4. Subjects on any other medical or clinical investigation or on any nutrition supplements and dietary regime. 5. Subjects visually or mentally handicapped or having difficulty to communicate 6. History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol. 7. Currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study. 8. Any additional condition(s) that in the Investigators opinion would warrant exclusion from the study or prevent the subject from completing the study.

Design outcomes

Primary

MeasureTime frame
Change in Cognitive Assessment ParametersTimepoint: Day 0, Day 42, Day 84

Secondary

MeasureTime frame
Change in BiomarkersTimepoint: Day 0, Day 42, Day 84;Safety of the test productTimepoint: Day 0, Day 42, Day 84

Countries

India

Contacts

Public ContactJestin V Thomas

Leads Clinical Research and Bio Services Pvt.Ltd

jestin.leadsclinbio@gmail.com9845125293

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026